Navigation Links
Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Date:6/24/2008

IRVINE, Calif., June 24 /PRNewswire/ -- Stason Pharmaceuticals, Inc., a vertically integrated cGMP contract development organization announced today that it has appointed Diana Wood as Vice President, Business Development. Ms. Wood will be responsible for all business development functions, including guiding Stason's global business development activities. Ms. Wood is a senior executive with extensive experience in sales, marketing, business and strategic planning, product development and general management on a worldwide basis. She will report directly to Chief Executive Officer Harry T. Fan. Most recently, Diana Wood served as the Executive Vice President, Business Development at Chiltern International, Inc., where she oversaw the company's global business development and marketing functions, and advised clients on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at Chugai Pharma USA in San Diego.

"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a highly respected track record and earned the trust of the pharmaceutical community. Diana will be a strategically important asset to our company. Furthermore, by bringing an extensive knowledge of the pharmaceutical industry and its regulatory environment combined with confidence and multifaceted business experience, she will continue to broaden and strengthen our relationship with our drug development partners."

"I am delighted to join Stason, a fast-growing and forward thinking organization," Ms. Wood said. "Today's product development landscape is changing rapidly and paradigms are shifting towards a more technologically driven development process from the bench to market. Stason embraced these changes early on, reducing overall development time and costs. I look forward to bringing new opportunities to Stason and to further expand our global growth."

About Stason Pharmaceuticals:

Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.


'/>"/>
SOURCE Stason Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
2. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
3. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
4. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Medimetriks Pharmaceuticals, Inc. Begins Operations
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
10. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
11. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):